Search clinical trials for: LEO 32731

Total 1680 results

LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Completed

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

LEO 32731 - A Study in Healthy Male Subjects

Healthy Subjects

United Kingdom
LEO Pharma

Completed

LEO 124249 Ointment in the Treatment of Alopecia Areata

Alopecia Areata

United States
LEO Pharma

Completed

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Actinic Keratosis

United States
LEO Pharma

Completed

Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam

Drug Interaction Potentiation

Germany
LEO Pharma

Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Hand Eczema

Germany
LEO Pharma

Terminated

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

Atopic Dermatitis

Germany
LEO Pharma

Terminated

A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
Cairo University

Unknown

Clinical Evaluation of Fracture Resistance and Color Changes of Laminate Veneer With Gull Wing Preparation

Discolored Teeth
JW Pharmaceutical
LEO Pharma

Completed

Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

Cholinergic Urticaria

Germany
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
LEO Pharma

Completed

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

Actinic Keratosis

Canada, United States
LEO Pharma

Completed

LEO 29102 Single and Multiple Dose Study by Dermal Application

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

Inverse Psoriasis

Germany
Balt Extrusion

Completed

Endovascular Treatment of Wide Neck Intracranial Aneurysms With the LEO + Stent : The LEO + II Cohort Study

Intracranial Aneurysm
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

Secondary Hyperparathyroidism

Germany, Poland
LEO Pharma
Quintiles, Inc.

Completed

A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects

Healthy

Japan
LEO Pharma
Quintiles, Inc.

Completed

A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects

Healthy

Japan
LEO Pharma

Completed

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland, Spain, Australia, Japan
Queen's University
The Ottawa Hospital; University of Ottawa

Completed

Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population

Varicose Ulcer

Canada
LEO Pharma

Active, not recruiting

Investigating the Safety of LEO 158968 in Healthy Volunteers

Healthy Volunteers

Netherlands
JW Pharmaceutical
LEO Pharma

Completed

A Trial to Evaluate the Effect of Food on LEO 152020

Healthy

United States, United Kingdom
LEO Pharma

Completed

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States, Canada
LEO Pharma

Completed

Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
LEO Pharma

Completed

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Actinic Keratosis

United States
LEO Pharma

Recruiting

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, France, Germany, Japan, Poland, United Kingdom, Czechia, Spain, Romania, Hungary
LEO Pharma

Completed

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Atopic Dermatitis

United States, Canada
LEO Pharma

Withdrawn

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

Healthy

United Kingdom
LEO Pharma

Completed

Assessment of the Phototoxic Potential of LEO 29102 Cream

Atopic Dermatitis

France
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
LEO Pharma
ICON plc

Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Healthy Volunteers

Netherlands
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
University College, London

Terminated

Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic (LIO-C)

COVID19

United Kingdom
LEO Pharma

Completed

Biological Effects of LEO 43204 in Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Atopic Dermatitis

United Kingdom

3

Subscribe